Trisubstituted 1,2,4-triazoles as ligands for the ghrelin receptor: On the significance of the orientation and substitution at position 3

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 1, 2008, Pages 164-168

  Moulin, Aline ^a   Demange, Luc ^a   Ryan, Joanne ^a   M'Kadmi, Céline ^a   Galleyrand, Jean Claude ^a   Martinez, Jean ^a   Fehrentz, Jean Alain ^a  

^a CNRS   (France)

Author keywords

1,2,4 Triazole; Agonist; Antagonist; Ghrelin; Ghrelin receptor ligands; GHS R1a; Trisubstituted 1,2,4 Triazoles

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; 2 METHYLALANYL DEXTRO TRYPTOPHAN 1 FORMAMIDO 2 (3 INDOLYL)ETHYLAMIDE; AMINO ACID; GHRELIN; GHRELIN RECEPTOR AGONIST; GHRELIN RECEPTOR ANTAGONIST; GROWTH HORMONE SECRETAGOGUE RECEPTOR; LIGAND; TRIPEPTIDE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING AFFINITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH HORMONE DEFICIENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE RECEPTOR INTERACTION; HUMAN; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

LIGANDS; RECEPTORS, GHRELIN; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 37649022059     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.113     Document Type: Article

References (17)

1. Demange L., Boeglin D., Moulin A., Mousseaux D., Ryan J., Berge G., Gagne D., Heitz A., Perrissoud D., Locatelli V., Torsello A., Galleyrand J.C., Fehrentz J.A., and Martinez J. J. Med. Chem. 50 (2007) 1939
2. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Nature 402 (1999) 656
3. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M.J., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., Chou M., Liu K., Mckee K.K., Pong S.S., Chaung L.Y., Elbrecht A., Heavens R., Rigby M., Sirinathsinghji D.J.S., Dean D.C., Melillo D.G., Patchett A.A., Nargund R., Griffin P.R., DeMartino J.A., Gupta S.K., Schaeffer J.M., Smith R.G., and Van Der Ploeg L.H.T. Science 273 (1996) 974
4. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., and Weigle D.S. Diabetes 50 (2001) 1714
5. Guerlavais V., Boeglin D., Mousseaux D., Oiry C., Heitz A., Deghenghi R., Locatelli V., Torsello A., Ghe C., Catapano F., Muccioli G., Galleyrand J.C., Fehrentz J.A., and Martinez J. J. Med. Chem. 46 (2003) 1191
6. Clausen K., Thorsen M., and Lawesson S.O. Tetrahedron 37 (1981) 3635
7. Hitotsuyanagi Y., Motegi S., Fukaya H., and Takeya K. J. Org. Chem. 67 (2002) 3266
8. Boeglin D., Cantel S., Heitz A., Martinez J., and Fehrentz J.A. Org. Lett. 5 (2003) 4465
9. Castro B., Dormoy J.R., Evin G., and Selve C. Tetrahedron Lett. (1975) 1219
10. 2, 2.5 mM EDTA and 0.015% (w/v) Triton X-100) and the radioactivity bound to membranes was measured in a gamma counter.
11. Mousseaux D., Le Gallic L., Ryan J., Oiry C., Gagne D., Fehrentz J.A., Galleyrand J.C., and Martinez J. Br. J. Pharmacol. 148 (2006) 350
12. 13
13. Cheng Y.-C., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
14. Patchett A.A., Nargund R.P., Tata J.R., Chen M.H., Barakat K.J., Johnston D.B., Cheng K., Chan W.W., Butler B., and Hickey G. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7001
15. Carpino P.A., Lefker B.A., Toler S.M., Pan L.C., Hadcock J.R., Cook E.R., DiBrino J.N., Campeta A.M., DeNinno S.L., Chidsey-Frink K.L., Hada W.A., Inthavongsay J., Mangano F.M., Mullins M.A., Nickerson D.F., Ng O., Pirie C.M., Ragan J.A., Rose C.R., Tess D.A., Wright A.S., Yu L., Zawistoski M.P., DaSilva-Jardine P.A., Wilson T.C., and Thompson D.D. Bioorg. Med. Chem. 11 (2003) 581
16. Moulin, A.; Demange, L.; Berge, G.; Gagne, D.; Ryan, J.; Mousseaux, D.; Heitz, A.; Perrissoud, D.; Locatelli, V.; Torsello, A.; Galleyrand, J. C.; Fehrentz, J.A.; Martinez, J. J. Med. Chem. 2007, DOI. 10.1021/jm0704550. unpublished results.
17. Unpublished results.